| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human IL-17RC-Fc-Tag protein was developed from hek293 and has a target region of Fc-Tag. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised 0.2 Mu m filtered PBS solution, pH7.2. |
| Storage Instruction: |
Can be stored in working aliquots at 2°C-8°C C for one month, or at-20°C to-70°C for 1 year. Avoid repeated freeze/thaw cycles. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Gene Symbol: |
IL17RC |
| Gene ID: |
84818 |
| Uniprot ID: |
I17RC_HUMAN |
| Immunogen Region: |
ECD |
| Immunogen: |
Optimized DNA sequence encoding extracellular domain of human IL-17RC receptor including a C terminal Human IgG1 Fc tag was expressed in HEK293 cells. NA |
| Tissue Specificity | Expressed in prostate, skeletal muscle, kidney and placenta (at protein level). Expressed in brain, cartilage, colon, heart, intestine, kidney, liver, lung, muscle, placenta, and prostate. Also detected in thyroid, trachea and adrenal gland. Low expression in thymus and leukocytes. |
| Function | Receptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Receptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Receptor for IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RA. Receptor for the heterodimer formed by IL17A and IL17B as part of a heterodimeric complex with IL17RA. Has also been shown to be the cognate receptor for IL17F and to bind IL17A with high affinity without the need for IL17RA. Upon binding of IL17F homodimer triggers downstream activation of TRAF6 and NF-kappa-B signaling pathway. Induces transcriptional activation of IL33, a potent cytokine that stimulates group 2 innate lymphoid cells and adaptive T-helper 2 cells involved in pulmonary allergic response to fungi. Promotes sympathetic innervation of peripheral organs by coordinating the communication between gamma-delta T cells and parenchymal cells. Stimulates sympathetic innervation of thermogenic adipose tissue by driving TGFB1 expression. Binding of IL17A-IL17F to IL17RA-IL17RC heterodimeric receptor complex triggers homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter through SEFIR domains. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Primarily induces neutrophil activation and recruitment at infection and inflammatory sites. Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers. Isoform 5: Receptor for both IL17A and IL17F. Isoform 6: Does not bind IL17A or IL17F. Isoform 7: Does not bind IL17A or IL17F. Isoform 8: Receptor for both IL17A and IL17F. |
| Protein Name | Interleukin-17 Receptor CIl-17 Receptor CIl-17rcInterleukin-17 Receptor HomologIl17rhomInterleukin-17 Receptor-Like ProteinIl-17rlZcytor14 |
| Database Links | Reactome: R-HSA-448424Reactome: R-HSA-9705671 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinSoluble Isoforms May Be Produced |
| Alternative Protein Names | Interleukin-17 Receptor C proteinIl-17 Receptor C proteinIl-17rc proteinInterleukin-17 Receptor Homolog proteinIl17rhom proteinInterleukin-17 Receptor-Like Protein proteinIl-17rl proteinZcytor14 proteinIL17RC proteinUNQ6118 proteinPRO20040 proteinPRO38901 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
